Company Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.

Employees

269

Sector

Pharmaceuticals

More about the company

03-17	Paratek Pharmaceuticals, Inc. acquired Radius Health, Inc. from B-Flexion Advisors (UK) LLP, Gurnet Point Capital Limited, OrbiMed Advisors LLC, Patient Square Capital, LP and Webster Equity Partners, L.P.	CI
02-24	Paratek Pharmaceuticals Announces Positive Results for NUZYRA Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement Under Barda Project Bioshield Contract	CI
25-10-17	Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025	CI
25-05-21	Paratek Pharmaceuticals, Inc completed the acquisition of OptiNose, Inc. from group of shareholders.	CI
25-03-18	Paratek Pharmaceuticals, Inc. entered into a definitive merger agreement to acquire OptiNose, Inc. for approximately $100 million.	CI
24-11-14	Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities	CI
24-11-08	Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline in Nontuberculous Mycobacterial Abscessus Pulmonary Disease	CI
24-07-31	Paratek Pharmaceuticals, Inc Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in Vitro Potency Against Indicated Pathogens	CI
24-07-18	Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia	CI
24-03-05	Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract	CI
24-01-16	Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer	CI
24-01-16	Paratek Pharmaceuticals, Inc. Promotes Christopher Bostrom to Chief Financial Officer	CI
23-09-22	Novo Holdings, Gurnet Point Close $462 Million Purchase of Paratek Pharmaceuticals	MT

23-06-07	HC Wainwright Downgrades Paratek Pharmaceuticals to Neutral From Buy, Price Target is $2.15	MT
23-06-07	Jefferies Downgrades Paratek Pharmaceuticals to Hold From Buy, Adjusts Price Target to $2.15 From $5	MT
23-03-20	HC Wainwright Adjusts Paratek Pharmaceuticals' Price Target to $10 From $20, Keeps Buy Rating	MT
22-04-11	BTIG Research Adjusts Paratek Pharmaceuticals Price Target to $30 From $34, Maintains Buy Rating	MT
22-03-17	HC Wainwright Adjusts Paratek Pharmaceuticals' Price Target to $22 From $27, Reiterates Buy Rating	MT

23-10-05	Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point And Novo Holdings Acquire Paratek Pharmaceuticals	AQ
23-10-05	Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023	AQ
23-09-21	Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.	AQ
23-09-18	Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S	AQ
23-09-12	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S	AQ

Manager	Title	Age	Since
Evan Loh CEO	Chief Executive Officer	67	2019-06-24
Christopher Bostrom DFI	Director of Finance/CFO	-	2024-01-15
Adam Woodrow PSD	President	59	2019-06-24

Director	Title	Age	Since
Evan Loh BRD	Director/Board Member	67	2014-05-31
Nithya Desikan BRD	Director/Board Member	-	-
Morten Aleksandr Engel BRD	Director/Board Member	-	-

Paratek Pharmaceuticals, Inc. Stock

Stocks

PRTK

US6993743029

Pharmaceuticals

Latest news: Paratek Pharmaceuticals, Inc.

Analysts' recommendations: Paratek Pharmaceuticals, Inc.

Press Releases: Paratek Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Paratek Pharmaceuticals, Inc.

Latest insider transactions

Other Pharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/21/23	William Haskel	Issuer sale	Compliance Officer	447,024	0.7798%
9/21/23	Evan Loh	Issuer sale	Chief Executive Officer	1,327,981	2.3167%
9/21/23	Robert Radie	Issuer sale	Director	135,000	0.2355%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PARATEK PHARMACEUTICALS, INC.	+1.83%	+1.36%	-	-	128M
ELI LILLY AND COMPANY	+0.04%	+3.34%	+51.12%	+101.82%	1,027B
JOHNSON & JOHNSON	-0.09%	+1.66%	+55.02%	+66.18%	651B
ABBVIE INC.	-0.02%	+2.66%	+18.91%	+71.47%	467B
ROCHE HOLDING AG	-1.22%	+3.66%	+36.44%	+38.32%	350B
NOVARTIS AG	-0.79%	+2.73%	+19.03%	+25.08%	268B
ASTRAZENECA PLC	+0.58%	+6.76%	+11.13%	+16.52%	257B
AMGEN INC.	+1.55%	+2.20%	+39.81%	+46.55%	205B
NOVO NORDISK A/S	+0.79%	+1.84%	-28.27%	-56.71%	190B
GILEAD SCIENCES, INC.	-0.52%	+4.45%	+32.12%	+98.51%	187B
Average	+0.36%	+2.96%	+26.15%	+45.30%	400.23B
Weighted average by Cap.	+0.23%	+3.01%	+35.17%	+61.81%